Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMY)
Filing Type: Form 8-K (Current Report)
Date of Report: January 13, 2025
Event: Regulation FD Disclosure regarding the posting of an investor presentation on the company website.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to disclose the availability of an investor presentation (Exhibit 99.1) and does not contain embedded financial data tables or narrative financial results.
Material Changes
No material changes to financial performance or operations are detailed within the text of this filing. The document references an attached investor presentation for detailed information but does not summarize those contents.
Guidance, Outlook, and Risks
Management Commentary: The Company posted an investor presentation dated January 13, 2025, to its website.
Legal Disclaimer: The information in Item 7.01 and Exhibit 99.1 is not deemed "filed" under the Securities Exchange Act of 1934 and is not subject to the liabilities of Section 18. It shall not be incorporated by reference into any other filing.
Risks and Contingencies: No specific risks or contingencies are described in the text of this 8-K.
Key Facts for Investor Verification
- Verify the content of the investor presentation attached as Exhibit 99.1 for actual financial guidance and operational updates.
- Note that the information in this 8-K is not incorporated by reference into other SEC filings.
- Confirm the trading status of registered securities listed: Common Stock (BMY), 1.000% Notes due 2025 (BMY25), 1.750% Notes due 2035 (BMY35), and Celgene Contingent Value Rights (CELG RT).